| Trial ID: | L2020 |
| Source ID: | NCT00282360
|
| Associated Drug: |
Trimetazidine
|
| Title: |
Effect of Metabolic Therapy in Patients With Chronic Ischemic Heart Disease
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Coronary Artery Disease|Type II Diabetes Mellitus
|
| Interventions: |
DRUG: Trimetazidine
|
| Outcome Measures: |
Primary: total ischemic burden|silent ischemia | Secondary: symptomatic myocardial ischemia
|
| Sponsor/Collaborators: |
Sponsor: IRCCS San Raffaele
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
30
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT
|
| Start Date: |
1999-02
|
| Completion Date: |
2003-10
|
| Results First Posted: |
|
| Last Update Posted: |
2006-01-26
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT00282360
|
